Immunotheropy Solutions Companies-2021
Pharma Tech Outlook
Nammi Therapeutics : Perfecting The Anti-Tumor Effec
line

Top 10 Immunotheropy Solution Companies - 2021

line

The new-age healthcare experts are delving deeper into the technology aspect of pharmaceutical solutions to open doors for immunotherapy innovations. And their quest has led them to precision medicine that can address a wide range of challenges related to cell therapy. Infused with sophisticated technologies like AI, IoT, and big data, the advanced cell therapy is now designed to feature decentralized way of manufacturing that requires precise culturing of individual cell components. In short, the latest precision medicine models hold keys to unlocking the functional potency of immunotherapy by gradually reducing the level of human involvement and making processes automated. Also, the need for process efficiency, product consistency, and cost-effectiveness is driving automation efforts widely in numerous cell therapy fields, especially T-cell immunotherapy care. Moreover, these never-seen-before methodologies help practitioners to understand individual immunologic responses better and enable them to provide a patient-specific treatment. On this front, promising technologies like intensity-modulated radiation therapy, image-guided radiation therapy, targeted therapy, and streamlined immunotherapy drugs.

To help leaders navigate through the list of immunotherapy solution providers, our panel comprising CEOs, CIOs, VCs, industry analysts, and the editorial board of Pharma Tech Outlook has narrowed down the top solution providers in this landscape that exhibit competence in delivering immunotherapy innovations. Equipped with innovative technological capabilities, these enlisted solution providers are transforming the healthcare paradigm at the cloverleaf of various disruptive immunotherapy technologies. Besides, the magazine comprises insights from subject-matter experts, CIOs, and CXOs in the pharma sector on the latest industry trends, best practices, recent innovations, and highlights their expertise. We hope this issue of Pharma Tech Outlook helps you build the partnership you and your organization need to foster an environment driven by robust and efficient technology.

We present to you Pharma Tech Outlook’s “Top 10 Immunotherapy Solution Companies - 2021.”

    Immunotheropy Solutions Companies

    Aavocyte focuses on developing various T cell immune therapy products to treat cancers based on our unique precise targeting rAAV delivery platform ... read full profile
    A biopharmaceutical company focused on developing novel therapies for prevalent inflammatory conditions for which limited treatment options exist. Ampio is developing a non-steroidal anti-inflammatory drug, Ampion™, currently in clinical trials, which can be administered for a long time at an affordable cost. Because Ampion is a platform biologic built on a unique immunomodulating mechanism of action that suppresses inflammation while promoting healing, it has application across different routes of delivery or drug administration. Ampio has developed manufacturing capability in-house to control costs to support the flexible pricing needed to span multiple different indications with a global distribution ... read full profile
    An innovator in developing and supplying automated immunohistochemistry instrumentation, and the full range of antibodies and reagents for IHC, ISH, and HPV lab testing ... read full profile
    Entera Health is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs in gastroenterology, oncology, and infectious disease management ... read full profile
    Eurofins Viracor BioPharma has been offering prolific services for complex testing and assay development with over 30 years of industrial experience. Their core areas of expertise include molecular and immunological assays, specifically immunogenicity, immunological responses, and hypersensitivity, supporting clinical trials for infectious disease and oncology therapeutic development. Eurofins Viracor BioPharma also leverages its vast network of Eurofins partner laboratories and scientists beyond the in-house expertise to cater to diverse client needs. Further, the company has partnered with Illumina, the prominent biotechnology company, to introduce a next-generation sequencing service, PanCancerIQTM that facilitates comprehensive genomic profiling of tumor samples. Eurofins Viracor BioPharma also partnered with Moderna for clinical trial testing for the COVID-19 vaccine in the wake of the pandemic ... read full profile
    InVitria develops, manufactures, and markets high performance products used in cell culture, vaccines, biopharmaceutical formulation, gene therapy, CAR T cell therapy, stem cells, medical devices and regenerative medicine ... read full profile
    Nammi Therapeutics aims to improve cancer care by co-delivering combinations of immunotherapy to tumor using proprietary technologies. Nammi’s nano-enabled approach utilizes a combination of drugs that act synergistically to switch on the immune response at the cancer site while also preventing immune escape. The company has developed two technology platforms, the Nammisomes and the Masked ImmunoCytokines, which, to which they apply their three key design features — synergistic combinations, masking mechanism, and activation and targeting mechanisms for optimal immunotherapies. The company is developing products that focus immune activation at the site of tumors, sparing the life-changing side effects of systemic immune activation ... read full profile
    Qualigen Therapeutics is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack diagnostic system. Qualigen is well situated in the southern California biotech hub that allows the company to take advantage of the scientific bench strength, while leveraging the company’s strong medical-devices development and commercial track records. The most advanced therapeutic candidate in the Qualigen pipeline is QN-165, a broad-based antiviral drug candidate in-licensed from the University of Louisville with an initial targeted indication for the treatment of COVID-19 ... read full profile
    STCube develops therapies to overcome novel and improved immune evasion mechanisms in cancer ... read full profile
    Tevogen Bio was founded with the aim of delivering greater health equity by making the very expensive and sophisticated personalized immunotherapies available to everyone. The preclinical studies conducted by Tevogen Bio have revealed that their proprietary technologies have been successful in generating T-cells at scale, with unmatched purity and high cytolytic ability (the ability to destroy a viral infected cell or cancer cell). While it was only possible to get one or two treatment doses from a single donor earlier, Tevogen Bio’s proprietary technologies make it possible to obtain a thousand doses of highly purified cells from a single donor. This development indeed marks a significant breakthrough in bringing down the costs of personalized immunotherapies drastically. Extending their scope to viral illnesses, Tevogen Bio’s proprietary technologies promise to play a vital role in fighting viruses like SARS-CoV-2. ... read full profile